Collegium Pharmaceutical (COLL) Other Non-Current Liabilities (2018 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Other Non-Current Liabilities of $19000.0 for Q3 2025, down 99.54% year-over-year from $4.1 million in Q3 2024, and down 50.0% quarter-over-quarter from $38000.0 in Q2 2025.
Collegium Pharmaceutical (COLL) Other Non-Current Liabilities (2018 - 2026) Analysis & Trends
Collegium Pharmaceutical's Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $19000.0 for Q3 2025.
- In Q3 2025, Other Non-Current Liabilities fell 99.54% year-over-year to $19000.0; the TTM figure through Sep 2025 stood at $19000.0 (down 99.54% YoY), while the FY2024 annual figure was $1.2 million, changed N/A from the prior year.
- Other Non-Current Liabilities for Q3 2025 stood at $19000.0, down from $38000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $4.1 million in Q3 2024, with the low at $19000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Collegium Pharmaceutical | 879.69 Mn | 730.37 Mn | 110.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.53 Mn |
| Sep 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 38,000.00 |
| Mar 31, 2025 | 396,000.00 |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 4.10 Mn |
| Dec 31, 2018 | 676,000.00 |
| Sep 30, 2018 | 284.83 Mn |
| Jun 30, 2018 | 314.45 Mn |
| Mar 31, 2018 | 343.73 Mn |